Karolinska Institute

KFSH&RC Welcomes Dr. Björn Zoéga as New Deputy CEO

Retrieved on: 
Tuesday, April 2, 2024
Karolinska University Hospital, Health, Education, Research, RC, Karolinska Institute, Landspítali, KFSH, National University Hospital

RIYADH, Saudi Arabia, April 02, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH&RC) is proud to announce the appointment of Dr. Björn Zoéga as Deputy Chief Executive Officer (CEO), effective 01 April 2024. This strategic move is set to accelerate KFSH&RC's aspiration of becoming a leading healthcare institution on the global stage, leveraging Dr. Zoéga's notable career and proven track record of leadership in top-tier medical institutions.

Key Points: 
  • RIYADH, Saudi Arabia, April 02, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre (KFSH&RC) is proud to announce the appointment of Dr. Björn Zoéga as Deputy Chief Executive Officer (CEO), effective 01 April 2024.
  • His administration at Karolinska was marked by innovative strategies and excellence in healthcare delivery—all which he is posed to enrich within KFSH&RC.
  • Dr. Zoégabrings decades of healthcare management and clinical expertise to KFSH&RC, having spearheaded operations as CEO of the National University Hospital of Iceland and the Stockholm Spine Center.
  • As Deputy CEO, Dr. Zoéga will serve as chief lead of KFSH&RC’s healthcare delivery and research and innovation groups, following on the hospital’s commitment to integrating global best practices in healthcare and pursuing cutting-edge medical research and technology.

Dominari Securities LLC Expands Investment Banking Practice with Appointment of Experienced Financial Executive

Retrieved on: 
Tuesday, March 12, 2024
Biochemistry, MSRB, McGill University, Medical research, Research fellow, Health, Oncogene, FDIC, Karolinska Institute, Research, CRS, Investment Banking Exam, Investment banking, Senior, Virology, Investment, Breast cancer, Mission, FINRA, SIPC, Security (finance)

NEW YORK, March 12, 2024 /PRNewswire/ -- Dominari Holdings Inc. (Nasdaq: DOMH) (the "Company") today announced its wholly-owned subsidiary, Dominari Securities LLC, has appointed Dr. Cosme Ordoñez to the role of Head of Investment Banking, Investment Banking Principal and bolstering the firm's coverage in the healthcare sector.

Key Points: 
  • Mr. Kyle Wool, CEO of Dominari Securities LLC, commented, "We are thrilled to welcome Cosme to the firm to head up our investment banking practice.
  • Securities Brokerage and Registered Investment Adviser Services are offered through Dominari Securities LLC, a Member of FINRA, MSRB and SIPC.
  • You can check the background of Dominari Securities and its registered investment professionals and review its SEC Form CRS on FINRA's BrokerCheck site at https://brokercheck.finra.org .
  • Information for Dominari Securities LLC and its registered investment professionals as well as its SEC Form CRS may also be found on FINRA's BrokerCheck site.

Welcome to SciBase Capital Markets Day 2024

Retrieved on: 
Thursday, January 25, 2024
Patient, Capital market, Karolinska Institute, Electrode, Skin cancer, SCIB, Digital, MBA, CPC, Management

STOCKHOLM, Jan. 25, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in early detection and prevention in dermatology hereby invites investors, analysts, and financial media to SciBase Capital Markets Day today on January 25, 2024.

Key Points: 
  • STOCKHOLM, Jan. 25, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a pioneer in early detection and prevention in dermatology hereby invites investors, analysts, and financial media to SciBase Capital Markets Day today on January 25, 2024.
  • During SciBase's Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will provide insights into SciBase's future trajectory, and unveil an updated strategic outlook, and long-term strategic goals.
  • The presentations will underscore the company's focus on the USA and shed light on SciBase's ongoing expansion into promising new markets.
  • Although the Company has a strategic focus on the USA, Germany continues to be an important and profitable market for SciBase.

Combination Therapy and Precision Medicine Spotlighted as the Gold Standard for the Next Generation of Alzheimer's Treatments in the Journal of Prevention of Alzheimer's Disease (JPAD)

Retrieved on: 
Tuesday, January 16, 2024
Fillit, Entrepreneurship, Drug, School, Patient, Biology, Risk, Reno 1868 FC, Science, Research, MD, Oxidative stress, Next Generation, Biomarker, Drug development, Internal medicine, University, Geriatrics, Cancer, Ageing, Neuroprotection, UNLV, Journal, Karolinska Institute, Doctor of Science, Medicine, Autophagy, Therapy, Doctor of Philosophy, Syndrome, IHU, Dementia, Pharmaceutical industry

NEW YORK, Jan. 16, 2024 /PRNewswire/ -- The Journal of Prevention of Alzheimer's Disease (JPAD) with the support of the Alzheimer's Drug Discovery Foundation (ADDF) recently published a comprehensive issue, "The Biology of Aging: Leading The Next Generation of Alzheimer's Drug Development With a Geroscience Focus," which supports the consensus that combination therapy and precision medicine are the future of Alzheimer's treatment. This landmark publication arrives at a critical time in the Alzheimer's research field following significant drug breakthroughs of anti-amyloid therapies and the emergence of the biology of aging as the leading approach for drug development. This issue emphasizes the need to advance new therapies that target the underlying biology of the disease while also offering a roadmap for the next generation of Alzheimer's therapies.

Key Points: 
  • This issue emphasizes the need to advance new therapies that target the underlying biology of the disease while also offering a roadmap for the next generation of Alzheimer's therapies.
  • Each of these novel targets introduces a new and much-needed multi-pronged approach for developing Alzheimer's treatments, which can complement anti-amyloid drugs on the market.
  • The development of future therapies will enhance our growing understanding of the disease and how the various pathways interact to affect the disease state."
  • "This is a noteworthy achievement, as the publication will serve as the first extensive roadmap of non-amyloid pathways with the potential to address the complexity of Alzheimer's disease."

Welcome to SciBase Capital Markets Day 2024

Retrieved on: 
Tuesday, January 9, 2024
NBC, Capital market, Science, MD, Skin, Karolinska Institute, Health, Rigel, AAD, Skin cancer, George Washington University, ABC, American Academy, SCIB, Worldwide Angel, Clinical, Government, Digital, Strategic planning, MIT, MBA, NYU, Fox, Congress, FDA, American Academy of Dermatology, Subway Series, CNN, Pinnacle, Publication

STOCKHOLM, Jan. 9, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby invites investors, analysts, and financial media to SciBase capital markets day on January 25, 2024.

Key Points: 
  • STOCKHOLM, Jan. 9, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby invites investors, analysts, and financial media to SciBase capital markets day on January 25, 2024.
  • During SciBase's Capital Markets Day, Pia Renaudin, who assumed the role of CEO in October 2023, will provide insights into SciBase's future trajectory, and unveil an updated strategic outlook, and long-term strategic goals.
  • The presentations will underscore the company's focus on the USA and shed light on SciBase's ongoing expansion into promising new markets.
  • Two external speakers will participate in the event, further supporting the US role in the SciBase strategy going forward.

Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024

Retrieved on: 
Thursday, January 4, 2024
Physician, CD34, Risk, Infection, Mesa, Letter, Cell, Cytokine release syndrome, Master of Science, Karolinska Institute, Research, MDS, Therapy, Cancer, Infrared spectroscopy correlation table, Ligand, University, GEAR, COVID-19, HSPC, Observation, Toxicity, Interim, GVHD, CRS, Growth, Patient, Safety, AML, NK, Pharmaceutical industry

WEXFORD, Pa., Jan. 4, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that Dave Mehalick, President and CEO of Coeptis Therapeutics Holdings, has issued a Letter to Shareholders providing a review of its 2023 achievements and anticipated milestones for 2024.

Key Points: 
  • WEXFORD, Pa., Jan. 4, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that Dave Mehalick, President and CEO of Coeptis Therapeutics Holdings, has issued a Letter to Shareholders providing a review of its 2023 achievements and anticipated milestones for 2024.
  • Our strategy is to leverage these innovative and complementary platforms to develop powerful, personalized cell-based treatments to improve outcomes for patients with cancer.
  • As we look to 2024, we see enormous potential to advance our pipeline and achieve meaningful growth milestones.
  • On behalf of the entire Coeptis team, I wish you all a happy and healthy 2024.

Alzheon CEO Dr. Martin Tolar to Present ALZ-801/Valiltramiprosate Investigational Oral Alzheimer’s Treatment Program at Nobel Forum at Karolinska Institute in Stockholm, Sweden

Retrieved on: 
Wednesday, January 3, 2024
Science, Neurology, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Karolinska Institute, Cognition, Cerebrospinal fluid, Implementation, Risk, Cerebral edema, MD, Doctor of Philosophy, Nerve, Early, Neurotoxicity, Amyloid, Patient, Safety, Therapy, Pharmaceutical industry

Alzheon Founder, President, and CEO, Martin Tolar, MD, PhD, will present an overview of investigational oral ALZ-801/valiltramiprosate anti-amyloid oligomer treatment program in the section “Optimal Treatment for Future – Combination Therapy?” moderated by Kaj Blennow, MD, PhD, on January 19 at 1:30 PM CET (7:30 AM EST).

Key Points: 
  • Alzheon Founder, President, and CEO, Martin Tolar, MD, PhD, will present an overview of investigational oral ALZ-801/valiltramiprosate anti-amyloid oligomer treatment program in the section “Optimal Treatment for Future – Combination Therapy?” moderated by Kaj Blennow, MD, PhD, on January 19 at 1:30 PM CET (7:30 AM EST).
  • “We are honored to have received an invitation to present at the prestigious Nobel Forum and discuss how ALZ-801 tablet could help shape the future therapeutic landscape for Alzheimer’s disease.
  • Alzheon's simplified approach with an oral tablet has an opportunity to transform the standard of care for millions of patients,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.
  • “ALZ-801 efficacy data and a favorable safety profile, showing no increased risk of vasogenic edema, underscore the differentiated clinical profile of the treatment.

iCAD’s ProFound AI Can Predict 1-2 Year Risk for Breast Cancer and Reveal Insights for Heart Disease

Retrieved on: 
Monday, November 27, 2023
Radiology, Risk, Woman, Session, FDA, Death, Breast cancer, Ductal carcinoma, Breast, Hand tool, University, Overdiagnosis, DCIS, 2D, Karolinska Institute, High Risk, Digital, Physician, Inc., AI, CST, Neoplasm, Artificial intelligence, RSVP, Patient, Intelligence, Calcification, Partnership, Mammography, ICAD, Sale, Research, Blood, Biostatistics, CE, Google Health, Faculty, Cardiovascular disease, RSNA, Medical imaging

NASHUA, N.H., Nov. 27, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in innovative cancer-detection solutions, will present new studies validating its artificial intelligence (AI) powered ProFound Breast Health Suite for uncovering hidden heart or vascular disease and predicting a woman’s risk for developing breast cancer in the next one- or two-years. Researchers will present their findings at the Radiological Society of North America’s (RSNA) annual meeting in Chicago, Nov. 27 – 30, 2023.

Key Points: 
  • Blending artificial intelligence with computer-aided detection (AI CAD), the iCAD software platform, ProFound Breast Health Suite, can screen a single mammogram for two of the top causes of death for women: breast cancer and heart disease.
  • In fact, women with breast arterial calcifications, or BAC, are 51% more likely to develop heart disease.
  • He and his colleagues found the ProFound Heart Health AI algorithm highly accurate in uncovering BAC in mammograms.
  • ProFound Heart Health***: a new solution for measuring cardiovascular calcium deposits, alerting to possible vascular or heart disease (pending FDA clearance).

Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial

Retrieved on: 
Monday, November 20, 2023
MBD, Mammography, Risk, Woman, Breast cancer, Government, Principal, Ductal carcinoma, Breast, Therapy, Karolinska Institute, Cancer, Biostatistics, Pharmaceutical industry

MBD change is used as a proxy for therapy response.

Key Points: 
  • MBD change is used as a proxy for therapy response.
  • “Many of the risk factors for breast cancer, including breast density, are known, which means treating at-risk patient populations before the disease develops could significantly lower incidence rates,” said Dr.
  • “While significant progress has been made in breast cancer treatment, the same cannot be said about breast cancer prevention, particularly in high-risk women.
  • Both diagnoses are strong, independent predictors of breast cancer risk that we feel are modifiable with (Z)-endoxifen.”

SciBase capital markets day 2024 - save the date

Retrieved on: 
Thursday, December 28, 2023
Skin, Skin cancer, Digital, Karolinska Institute, SCIB, Pinnacle, Physician

STOCKHOLM, Dec. 28, 2023 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, hereby invites investors, analysts and financial media to SciBase capital markets day on January 25, 2024.

Key Points: 
  • STOCKHOLM, Dec. 28, 2023 /PRNewswire/ -- SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, hereby invites investors, analysts and financial media to SciBase capital markets day on January 25, 2024.
  • During SciBase's capital markets day, Pia Renaudin, CEO since October 2023, will discuss SciBase's way forward, updated strategy and long-term goals.
  • The presentations will focus on the USA as well as SciBase's ongoing establishment in new promising markets.
  • Pinnacle, an independent specialist company in the US reimbursement system, will explain the SciBase path towards reimbursement in the US.